This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Buy National Vision (EYE) Stock Now
by Zacks Equity Research
Investors remain optimistic about National Vision (EYE) on increased eyeglass comparable demand and encouraging 2021 strategies.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.
Medtronic (MDT) Diabetes Arm Grows With Favorable InPen Data
by Zacks Equity Research
Medtronic's (MDT) InPen is a FDA as well as CE Mark-cleared smart insulin pen available for patients who require multiple daily injections.
Pacific Biosciences (PACB)-RCIGM Tie Up for Sequencing Research
by Zacks Equity Research
Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.
SmileDirectClub (SDC) Reels Under Cyber Attack, Pandemic Woes
by Zacks Equity Research
SmileDirectClub (SDC) apprehends systems outage to have an adverse impact on its second-quarter revenues to the tune of approximately $10-$15 million.
Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.
Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout
by Zacks Equity Research
Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.
Boston Scientific (BSX) Eyeing Remaining 73% Farapulse Stake
by Zacks Equity Research
Boston Scientific (BSX) currently holds an equity stake of roughly 27%.
Medtronic (MDT) Global Market Share Rises Amid Pandemic Blues
by Zacks Equity Research
Most of Medtronic (MDT) end markets are gradually returning to near-normal pre-COVID growth.
OPKO Health (OPK) and Nicoya Sign RAYALDEE Deal
by Zacks Equity Research
OPKO Health's (OPK) subsidiary EirGen Pharma to develop and commercialize RAYALDEE in Greater China in collaboration with an affiliate of Nicoya Therapeutics.
The Zacks Analyst Blog Highlights: Henry Schein, BellRing Brands, Maravai LifeSciences and National Vision Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Henry Schein, BellRing Brands, Maravai LifeSciences and National Vision Holdings
4 Safe MedTech Bets Before Delta Strain Disrupts the Market Again
by Urmimala Biswas
Here are four MedTech stocks, HSIC, BRBR, MRVI and EYE, with favorable Zacks Rank and stellar growth parameters.
Medtronic (MDT) Reports First Surgery With Hugo RAS System (Revised)
by Zacks Equity Research
Medtronic (MDT) to begin patient registry for the Hugo RAS system following first successful patient procedure at Clinica Santa Maria in Chile.
BD's (BDX) PeritX System Gets FDA's Expanded 510(k) Clearance
by Zacks Equity Research
BD's (BDX) receipt of the expanded FDA indication for its PeritX System is expected to lessen the number of hospital trips a patient takes for fluid removal.
Zacks.com featured highlights include: Medifast, Boyd Gaming, National Vision Holdings, Gentherm and Generac
by Zacks Equity Research
Zacks.com featured highlights include: Medifast, Boyd Gaming, National Vision Holdings, Gentherm and Generac
Medtronic (MDT) Reports First Surgery With Hugo RAS System
by Zacks Equity Research
Medtronic (MDT) to begin patient registry for the Hugo RAS system following first successful patient procedure at Clinica Santa Maria in Chile.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.
PerkinElmer (PKI) to Boost Portfolio via SIRION Acquisition
by Zacks Equity Research
PerkinElmer (PKI) expects to be able to support its cell and gene therapy workflows, and expand its existing research solutions via the latest buyout.
5 Top-Ranked Liquid Stocks to Enrich Your Portfolio in 2021
by Aniruddha Ganguly
Here are five top-ranked liquid stocks -- Medifast (MED), Boyd Gaming (BYD), National Vision Holdings (EYE), Gentherm (THRM) and Generac Holdings (GNRC) -- which investors can tap for alluring returns.
AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.
Masimo's (MASI) Wearable Wireless Thermometer Gets FDA Nod
by Zacks Equity Research
Masimo's (MASI) continuous, wearable thermometer is likely to help monitor and track body temperature in all thermometer applications following the FDA's clearance.
NEOGEN's (NEOG) Soleris Test to Serve the Cannabis Industry
by Zacks Equity Research
NEOGEN's (NEOG) Soleris Direct Yeast and Mold test is approved by the AOAC Institute to identify yeasts and molds in dried cannabis flower.
OPKO Health (OPK) Inks Agreement to Sell Its Ireland Facility
by Zacks Equity Research
OPKO Health (OPK) expects to improve its business efficacy and focus on oral solid dose products post the sale of its Ireland facility.
ResMed (RMD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) on solid digital health growth potential along with rising demand for masks and other accessories.
CVS Health (CVS) Digital Tools Gain Steam Amid COVID-19 Crisis
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital strategy is more relevant in the current environment as people are increasingly using technology while staying indoors.